Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron Chalker

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
BMJ Supportive & Palliative Care|April 7, 2019
Efficacy of low-dose and/or adjuvant methadone in palliative medicineCameron Chalker, Hannah O'Neill, Faith Cranfield
Current Problems in Cancer|May 8, 2024
Germline and somatic mutations in prostate cancer: Implications for treatmentCameron Chalker, Brie Chun, Alexandra O Sokolova
Andrology|November 29, 2024
Prostate cancer and genetic contributionsWesley H Chou, Cameron Chalker, Alexandra O Sokolova, et al.
Clinical Genitourinary Cancer|May 21, 2026
Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World AnalysisColin P Bergstrom, Cameron Chalker, Joseph Allen, et al.
NPJ Precision Oncology|June 15, 2024
Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid noduleCameron Chalker, Burçak Yilmaz, Kristin Trone, et al.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
BMJ Supportive & Palliative Care|April 7, 2019
Efficacy of low-dose and/or adjuvant methadone in palliative medicineCameron Chalker, Hannah O'Neill, Faith Cranfield
Current Problems in Cancer|May 8, 2024
Germline and somatic mutations in prostate cancer: Implications for treatmentCameron Chalker, Brie Chun, Alexandra O Sokolova
Andrology|November 29, 2024
Prostate cancer and genetic contributionsWesley H Chou, Cameron Chalker, Alexandra O Sokolova, et al.
Clinical Genitourinary Cancer|May 21, 2026
Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World AnalysisColin P Bergstrom, Cameron Chalker, Joseph Allen, et al.
NPJ Precision Oncology|June 15, 2024
Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid noduleCameron Chalker, Burçak Yilmaz, Kristin Trone, et al.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Pageof 1